Opportunity Information: Apply for PA 07 166

  • The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Functional Genetics And Genomics Of Drug Addiction (R01)" and is now available to receive applicants.
  • Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
  • This funding opportunity was created on Dec 5, 2008 and posted on Dec 14, 2006.
  • Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
  • Eligible applicants include: County governments Small businesses For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Public housing authorities/Indian housing authorities City or township governments State governments Special district governments Public and State controlled institutions of higher education Private institutions of higher education Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Native American tribal organizations (other than Federally recognized tribal governments).
  • Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith based or community based organizations can apply.
Apply for PA 07 166

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:

Opportunity Summary:

The NIH funding opportunity PA 07 166, titled "Functional Genetics and Genomics of Drug Addiction (R01)," supports basic research that moves beyond simply identifying addiction-related genes and genetic variants and instead asks applicants to prove what those candidates actually do. The main idea is that large-scale genetic and genomic studies have already produced many promising signals tied to addiction risk and addiction biology, but those discoveries are only a starting point. This announcement is focused on the next step: experimental work that validates which genes or variants truly play a causal or mechanistically meaningful role in addictive processes, and then clarifies the biological pathways those genes or variants influence. In other words, the program is aimed at converting gene lists into real mechanistic understanding of addiction.

Scientifically, the FOA emphasizes two connected areas. First is functional validation, meaning studies designed to test whether a candidate gene or specific variant genuinely affects addiction-relevant traits or processes rather than being a statistical byproduct, a correlated marker, or a signal without biological consequence. Second is deeper mechanistic follow-up to map the molecular pathways, cellular processes, and biological systems that the validated genes or variants regulate. The FOA places particular value on cases where the gene appears to have an unexpected or previously unappreciated role in addiction, since those findings can open up new models of addiction biology and potentially point toward novel intervention strategies down the line. The overall scope is "functional genetics and functional genomics" in drug addiction, which generally implies experimentally grounded approaches that connect genotype to function, and function to addiction-related biology.

From a funding and administrative standpoint, this is an R01 opportunity, meaning it uses the NIH Research Project Grant mechanism intended for more mature, substantial projects with clear aims, strong preliminary rationale, and a multi-year plan. The announcement notes it runs in parallel with two other FOAs of the same scientific scope but different grant sizes and timelines: PA 07 167 for the R21 (exploratory/developmental) mechanism and PA 07 168 for the R03 (small grant) mechanism. That structure is meant to accommodate different stages of project maturity, with PA 07 166 being the pathway for full-scale projects that require a standard R01 budget and project period.

The number of awards and the amount of funding are not specified as fixed commitments. Instead, awards depend on NIH fund availability and whether enough high-quality, competitive applications are submitted. As with most NIH programs, this means applicants should plan as if the competition will be driven heavily by scientific merit, feasibility, significance to addiction research, and the strength of the proposed functional strategy rather than by a guaranteed set-aside.

Eligibility is broad and includes a wide range of domestic and international organizations. Eligible applicants include public and private institutions of higher education; nonprofits both with and without 501(c)(3) status; small businesses and other for-profit organizations; state and local government entities (including county and city/township governments, special districts, and independent school districts); U.S. territories and possessions; federally recognized and non-federally recognized tribal governments and tribally designated organizations; regional organizations; and eligible federal agencies. The FOA explicitly states that foreign (non-U.S.) institutions may apply, and that faith-based or community-based organizations are also eligible. The funding instrument is a grant, it is categorized under the health and education-related federal assistance area, and it falls under CFDA 93.279 (Drug Abuse and Addiction Research Programs). There is no cost sharing or matching requirement.

In terms of timing, the opportunity was posted December 14, 2006, and uses multiple receipt dates rather than one single deadline, with applicants directed to the full announcement for the specific schedule. The record also shows an archive date of February 2, 2010, indicating it is no longer active in its original form, but it remains a useful reference point for the type of science NIH was seeking under this initiative. The sponsoring agency is the National Institutes of Health, and the announcement includes standard NIH Office of Extramural Research contact guidance for technical problems accessing the full posting.

Overall, PA 07 166 is best understood as an NIH push to bridge the gap between association and mechanism in addiction genetics: taking candidate genes and variants emerging from genetic/genomic discovery and doing the careful functional work needed to establish causality, define biological pathways, and reveal how genetic differences shape the neurobiology and molecular biology of addictive behavior and drug responses.

FAQs: NIH PA-07-166 - Functional Genetics and Genomics of Drug Addiction (R01)

What is the NIH funding opportunity PA-07-166 about?

PA-07-166, titled "Functional Genetics and Genomics of Drug Addiction (R01)," supports basic research that moves beyond identifying addiction-related genes or variants and instead tests what those candidates actually do. The emphasis is on experimental work that validates whether candidate genes/variants have a causal or mechanistically meaningful role in addiction, and then clarifies the biological pathways they influence.

What problem is this FOA trying to solve in addiction genetics research?

Large-scale genetic and genomic studies have produced many promising signals linked to addiction risk and addiction biology. This FOA focuses on the next step: converting those gene/variant "signals" and gene lists into mechanistic understanding by showing functional impact and mapping pathways, rather than stopping at association.

What kinds of studies does the FOA prioritize?

The FOA emphasizes two connected areas: (1) functional validation studies designed to test whether a candidate gene or specific variant truly affects addiction-relevant traits or processes, and (2) mechanistic follow-up studies that identify the molecular pathways, cellular processes, and biological systems regulated by validated genes or variants.

What does "functional validation" mean in the context of this opportunity?

Functional validation refers to experimental studies that test whether a candidate gene or variant genuinely affects addiction-relevant biology. The intent is to distinguish causal or mechanistically important factors from signals that may be statistical byproducts, correlated markers, or findings without meaningful biological consequence.

What does the FOA mean by "mechanistic" follow-up?

Mechanistic follow-up means going beyond validation to determine how a validated gene or variant influences addiction-related biology. This includes mapping molecular pathways, cellular processes, and biological systems that the gene/variant regulates.

Does the FOA focus on gene discovery or on post-discovery work?

This FOA is primarily aimed at post-discovery work. It assumes that large-scale genetic/genomic discovery efforts have already generated candidate genes and variants, and it prioritizes experimental validation and pathway-level mechanistic understanding.

Are projects with unexpected gene functions particularly encouraged?

Yes. The FOA places particular value on cases where a gene appears to have an unexpected or previously unappreciated role in addiction, because those findings can open new models of addiction biology and may eventually point toward novel intervention strategies.

What grant mechanism does PA-07-166 use?

PA-07-166 uses the NIH R01 Research Project Grant mechanism, which is generally intended for more mature and substantial projects with clear aims, a strong preliminary rationale, and a multi-year research plan.

Are there related opportunities for smaller or earlier-stage projects?

Yes. The announcement runs in parallel with two other FOAs with the same scientific scope but different mechanisms: PA-07-167 (R21 exploratory/developmental) and PA-07-168 (R03 small grant). PA-07-166 is positioned for full-scale projects needing a standard R01 scope, budget, and project period.

Is the amount of funding or the number of awards guaranteed?

No. The number of awards and amount of funding are not specified as fixed commitments. Awards depend on NIH fund availability and the receipt of a sufficient number of high-quality, competitive applications.

What factors are implied to drive competitiveness for this FOA?

Based on the description, competition is expected to be driven by scientific merit, feasibility, significance to addiction research, and the strength of the proposed functional strategy, rather than by a guaranteed set-aside of funds or awards.

Who is eligible to apply?

Eligibility is broad. Eligible applicants include public and private institutions of higher education; nonprofits with or without 501(c)(3) status; small businesses and other for-profit organizations; state and local government entities (including county and city/township governments, special districts, and independent school districts); U.S. territories and possessions; federally recognized and non-federally recognized tribal governments and tribally designated organizations; regional organizations; and eligible federal agencies.

Can foreign (non-U.S.) institutions apply?

Yes. The FOA explicitly states that foreign (non-U.S.) institutions may apply.

Are faith-based or community-based organizations eligible?

Yes. The FOA explicitly states that faith-based or community-based organizations are eligible.

What is the funding instrument for this opportunity?

The funding instrument is a grant, using the NIH R01 mechanism.

Is cost sharing or matching required?

No. The opportunity states there is no cost sharing or matching requirement.

Which federal assistance category and program does this fall under?

The opportunity is categorized under health and education-related federal assistance and falls under CFDA 93.279 (Drug Abuse and Addiction Research Programs).

When was this opportunity posted, and does it have a single deadline?

The opportunity was posted on December 14, 2006. It uses multiple receipt dates rather than a single deadline, with applicants directed to the full announcement for the specific submission schedule.

Is PA-07-166 still active?

The record shows an archive date of February 2, 2010, indicating the opportunity is no longer active in its original form. However, it can still serve as a reference for the type of functional addiction genetics/genomics science NIH sought under this initiative.

Which agency sponsors this funding opportunity?

The sponsoring agency is the National Institutes of Health (NIH).

What should applicants do if they have technical problems accessing the full posting?

The announcement includes standard NIH Office of Extramural Research contact guidance for technical problems accessing the full posting.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Pathogenesis And Treatment Of Lymphedema And Lymphatic Diseases (R01)

Previous opportunity: Epidemiological and Behavioral Research in Oral Health (R01)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 07 166

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 07 166) also looked into and applied for these:

Funding Opportunity
Pathogenesis And Treatment Of Lymphedema And Lymphatic Diseases (R01) Apply for PA 07 165

Funding Number: PA 07 165
Agency: National Institutes of Health
Category: Education Health
Funding Amount: Case Dependent
Studies of Energy Balance and Cancer in Humans (R01) Apply for PA 07 176

Funding Number: PA 07 176
Agency: National Institutes of Health
Category: Education Health
Funding Amount: Case Dependent
Memory T Lymphocytes in Cancer Immunology (R01) Apply for PA 07 255

Funding Number: PA 07 255
Agency: National Institutes of Health
Category: Education Health
Funding Amount: Case Dependent
Cancer Surveillance Using Health Claims Based Data (R01) Apply for PA 07 254

Funding Number: PA 07 254
Agency: National Institutes of Health
Category: Education Health
Funding Amount: Case Dependent
Information Technologies and the Internet in Health Services and Intervention Delivery (R01) Apply for PA 07 295

Funding Number: PA 07 295
Agency: National Institutes of Health
Category: Education Health
Funding Amount: Case Dependent
Epigenetic Approaches in Cancer Epidemiology (R21) Apply for PA 07 299

Funding Number: PA 07 299
Agency: National Institutes of Health
Category: Education Health
Funding Amount: $200,000
Epigenetic Approaches in Cancer Epidemiology (R01) Apply for PA 07 298

Funding Number: PA 07 298
Agency: National Institutes of Health
Category: Education Health
Funding Amount: Case Dependent
Drug Abuse Aspects of HIV/AIDS (R21) Apply for PA 07 309

Funding Number: PA 07 309
Agency: National Institutes of Health
Category: Education Health
Funding Amount: Case Dependent
Drug Abuse Aspects of HIV/AIDS (R03) Apply for PA 07 308

Funding Number: PA 07 308
Agency: National Institutes of Health
Category: Education Health
Funding Amount: Case Dependent
Drug Abuse Aspects of HIV/AIDS (R01) Apply for PA 07 307

Funding Number: PA 07 307
Agency: National Institutes of Health
Category: Education Health
Funding Amount: Case Dependent
Research on Clinical Decision Making in Life Threatening Illness (R21) Apply for PA 07 316

Funding Number: PA 07 316
Agency: National Institutes of Health
Category: Education Health
Funding Amount: $200,000
Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM) NIDA (R03) Apply for PAS 07 327

Funding Number: PAS 07 327
Agency: National Institutes of Health
Category: Education Health
Funding Amount: Case Dependent
Drug Abuse, Risky Decision Making and HIV/AIDS (R03) Apply for PAS 07 326

Funding Number: PAS 07 326
Agency: National Institutes of Health
Category: Education Health
Funding Amount: Case Dependent
Drug Abuse, Risky Decision Making and HIV/AIDS (R01) Apply for PAS 07 324

Funding Number: PAS 07 324
Agency: National Institutes of Health
Category: Education Health
Funding Amount: Case Dependent
Drug Abuse, Risky Decision Making and HIV/AIDS (R21) Apply for PAS 07 325

Funding Number: PAS 07 325
Agency: National Institutes of Health
Category: Education Health
Funding Amount: $200,000
Academic Industrial Partnerships for Development and Validation of In Vivo Imaging Systems and Methods for Cancer Investigations (R01) Apply for PAR 07 214

Funding Number: PAR 07 214
Agency: National Institutes of Health
Category: Education Health
Funding Amount: Case Dependent
NIDA Research Education Grants in Drug Abuse and Addiction (R25) Apply for PAR 07 221

Funding Number: PAR 07 221
Agency: National Institutes of Health
Category: Education Health
Funding Amount: Case Dependent
Neuroscience Research on Drug Abuse (R01) Apply for PA 07 226

Funding Number: PA 07 226
Agency: National Institutes of Health
Category: Education Health
Funding Amount: Case Dependent
Neuroscience Research on Drug Abuse (R21) Apply for PA 07 227

Funding Number: PA 07 227
Agency: National Institutes of Health
Category: Education Health
Funding Amount: $200,000
Neuroscience Research on Drug Abuse(R03) Apply for PA 07 228

Funding Number: PA 07 228
Agency: National Institutes of Health
Category: Education Health
Funding Amount: $50,000

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

USGrants.org applicant portal membership

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 07 166", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.